MX2018005462A - Composiciones inmunogénicas de rsv quimérico y métodos de uso. - Google Patents

Composiciones inmunogénicas de rsv quimérico y métodos de uso.

Info

Publication number
MX2018005462A
MX2018005462A MX2018005462A MX2018005462A MX2018005462A MX 2018005462 A MX2018005462 A MX 2018005462A MX 2018005462 A MX2018005462 A MX 2018005462A MX 2018005462 A MX2018005462 A MX 2018005462A MX 2018005462 A MX2018005462 A MX 2018005462A
Authority
MX
Mexico
Prior art keywords
methods
immunogenic compositions
chimeric rsv
rsv
respiratory syncytial
Prior art date
Application number
MX2018005462A
Other languages
English (en)
Spanish (es)
Inventor
l moore Martin
ROSTAD Christina
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MX2018005462A publication Critical patent/MX2018005462A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • C12N2760/18562Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2018005462A 2015-10-29 2016-10-27 Composiciones inmunogénicas de rsv quimérico y métodos de uso. MX2018005462A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562247962P 2015-10-29 2015-10-29
US201662334547P 2016-05-11 2016-05-11
PCT/US2016/058976 WO2017075125A1 (en) 2015-10-29 2016-10-27 Chimeric RSV, Immunogenic Compositions, and Methods of Use

Publications (1)

Publication Number Publication Date
MX2018005462A true MX2018005462A (es) 2018-08-01

Family

ID=58630734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005462A MX2018005462A (es) 2015-10-29 2016-10-27 Composiciones inmunogénicas de rsv quimérico y métodos de uso.

Country Status (10)

Country Link
US (2) US11235050B2 (cg-RX-API-DMAC7.html)
EP (1) EP3368547A4 (cg-RX-API-DMAC7.html)
JP (2) JP7311872B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180085730A (cg-RX-API-DMAC7.html)
CN (1) CN108602858A (cg-RX-API-DMAC7.html)
BR (1) BR112018008708A2 (cg-RX-API-DMAC7.html)
CA (1) CA3003726A1 (cg-RX-API-DMAC7.html)
MX (1) MX2018005462A (cg-RX-API-DMAC7.html)
SG (1) SG11201803581VA (cg-RX-API-DMAC7.html)
WO (1) WO2017075125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189756B (zh) 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
EP4559869A3 (en) 2017-04-04 2025-08-20 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
PH12021550974A1 (en) * 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
CN117693360A (zh) * 2021-04-08 2024-03-12 科达金尼克斯有限公司 引发针对呼吸道合胞病毒的免疫应答的方法
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
AU727923B2 (en) 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
JP4413999B2 (ja) 1996-07-15 2010-02-10 アメリカ合衆国 クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
AU2001263443A1 (en) * 2000-05-25 2001-12-03 Med Immune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
JP4783726B2 (ja) 2003-03-28 2011-09-28 メディミューン,エルエルシー 呼吸器合胞体ウイルスサブグループb株9320に関連する組成物および方法
AU2004303719B2 (en) 2003-12-24 2010-11-11 Intravacc B.V. A respiratory syncytial virus with a genomic deficiency complemented in trans
WO2006042156A2 (en) 2004-10-08 2006-04-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS represneted by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Modulation of replicative fitness by using less frequently used synonymous codons
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EP2099486A2 (en) 2006-11-30 2009-09-16 Government Of The United States Of America, As Represented by the Secretary Codon modified immunogenic compositions and methods of use
PL2139515T5 (pl) 2007-03-30 2024-04-08 The Research Foundation Of The State University Of New York Atenuowane wirusy przydatne w szczepionkach
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
RU2011122615A (ru) 2008-11-05 2012-12-20 Мерк Шарп Энд Домэ Корп. Живой аттенуированный респираторно-синцитиальный вирус
EP3718566B1 (en) 2008-12-09 2024-06-12 Novavax, Inc. Modified rsv f proteins and methods of their use
CN102639147B (zh) 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
US20110097358A1 (en) 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
SG194755A1 (en) * 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
EP2729169A1 (en) 2011-07-06 2014-05-14 Nanobio Corporation Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
ES2952387T3 (es) 2013-02-08 2023-10-31 Us Health Atenuación del virus respiratorio sincitial humano mediante la desoptimización de pares de codones a escala genómica
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN105189756B (zh) 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions

Also Published As

Publication number Publication date
JP2019500320A (ja) 2019-01-10
WO2017075125A1 (en) 2017-05-04
US20230293660A1 (en) 2023-09-21
KR20180085730A (ko) 2018-07-27
SG11201803581VA (en) 2018-05-30
US11235050B2 (en) 2022-02-01
EP3368547A4 (en) 2019-06-05
JP2023100654A (ja) 2023-07-19
US12257296B2 (en) 2025-03-25
EP3368547A1 (en) 2018-09-05
CA3003726A1 (en) 2017-05-04
US20180333477A1 (en) 2018-11-22
BR112018008708A2 (en) 2018-11-06
CN108602858A (zh) 2018-09-28
JP7311872B2 (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
PH12018500856A1 (en) Respiratory syncytial virus vaccine
ZA202403393B (en) Synthetic chimeric poxviruses
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2017070626A3 (en) Respiratory virus vaccines
WO2018089851A3 (en) Influenza vaccine
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
PH12016501441B1 (en) Chimeric alkaline phosphatase-like proteins
EP4501318A3 (en) Nucleic acid vaccines
MX2016016722A (es) Coronavirus.
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2020011586A (es) Virus vaccinia quimerico sintetico.
MX2017000394A (es) Vacunas para virus influenza y usos de las mismas.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX387421B (es) Producción de virus en huevos aviares.
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
MY191539A (en) Streptococcal vaccine
SG10201808278TA (en) Polishing composition and polishing method
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
IL263370A (en) Improved RNA encoding vegf-a polypeptides, related compositions and uses
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
ZA201800940B (en) Use of il-3, il-33, and il-12p40 for characterization of the respiratory infections by syncytial respiratory virus
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
PL3344273T3 (pl) Kompozycje zawierające magnolię, korkowiec, teaninę i/lub białko serwatkowe
MX2018003173A (es) Vacunas de salmonella choleraesuis-salmonella typhimurium.